NCT00299000View on ClinicalTrials.gov

A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

PHASE4CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Mucopolysaccharidosis VIMaroteaux-Lamy Syndrome
Interventions
DRUG

Naglazyme

Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution

Trial Locations (4)

69677

Hospital Femme Mere Enfant Centre, Lyon

90027

Children's Hospital Los Angeles, Los Angeles

94609

Children's Hospital Oakland, Oakland

3000-076

Hospital PediAtrico de Coimbra, Coimbra

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY